Background 18 500 laboratory-confi rmed deaths caused by the 2009 pandemic infl uenza A H1N1 were reported worldwide for the period April, 2009, to August, 2010. This number is likely to be only a fraction of the true number of the deaths associated with 2009 pandemic infl uenza A H1N1. We aimed to estimate the global number of deaths during the fi rst 12 months of virus circulation in each country.
Introduction
Infl uenza pandemics are typically characterised by higher, but widely varying, number of deaths than are seasonal epidemics. 1 The emergence of pandemic infl uenza A H1N1 in April, 2009, led WHO to request that countries report all laboratory-confi rmed deaths associated with it. For the period up to August, 2010, 18 500 deaths associated with laboratory-confi rmed 2009 pandemic infl uenza A H1N1 have been reported. 2 This number is likely to be an underestimate because diagnostic specimens are not always obtained from people who die with infl uenza and the viruses might no longer be detectable by the time of death in some people.
Estimation of the 2009-pandemic-associated mortality presents several challenges. First, data for infl uenza in many countries are sparse and obtained through virological surveillance without standardised case reporting or population denominators needed to estimate incidence. Second, the level and timing of the circulation of the pandemic virus might vary by region and country. [3] [4] [5] Third, the severity of infl uenza might vary by region and country due to diff erences in access to and quality of health care, nutritional status, prevalence of underlying chronic disorders, age distribution of the populations, and the use of infl uenza vaccines and antiviral drugs. [6] [7] [8] [9] [10] Infl uenza-associated mortality is often estimated indirectly, by use of statistical models, as the number of excess deaths during periods of circulation of the virus. [11] [12] [13] Infl uenza-associated deaths that might be missed by direct counts of only laboratory-confi rmed deaths are taken into account with the use of these indirect approaches. However, indirect estimation might not be as easy to apply in settings where infl uenza viruses circulate perennially without a clearly defi ned season or where data for circulation with other respiratory viruses are not available. Additionally, methods to estimate excess mortality require the availability of vital statistics data that are sparse in some regions of the world and not always available in aggregate until 2-3 years after deaths are reported in countries that do have data. Thus, new methods are needed to produce timely and representative estimates of worldwide infl uenza-associated mortality.
A global estimate of the mortality associated with the 2009 pandemic infl uenza A H1N1 is needed to document the eff ect of the pandemic on the world's population and to help guide allocation and delivery of prevention and treatment measures during future pandemics. So far, most re ported estimates of mortality associated with 2009 pandemic infl uenza A H1N1 are from high-income, temperate countries. [14] [15] [16] [17] We developed a new approach to estimate global mortality and the number of years of life lost (YLL) associated with the fi rst year of circulation of the 2009 pandemic infl uenza A H1N1 virus in each country.
Methods

Estimation of respiratory mortality rate
To calculate the base respiratory mortality rate associated with the 2009 pandemic infl uenza A H1N1 (unadjusted for diff erences between regions in risk of death) for each country, we estimated the 12 month cumulative symptomatic attack rate (sAR) with data from highincome, middle-income, and low-income countries and multiplied it by the estimated symptomatic case fatality ratio (sCFR) from select high-income countries. sAR was defi ned as the percentage of the population who developed a symp tomatic respiratory illness associated with laboratory-confi rmed 2009 pandemic infl uenza A H1N1. sCFR was defi ned as the percentage of individuals with symptomatic respiratory illness associated with laboratoryconfi rmed 2009 pandemic infl uenza A H1N1 who died.
We stratifi ed the estimates of sAR and sCFR into three age groups: 0-17 years (paediatric age group), 18-64 years, and greater than 64 years. We did not further stratify the paediatric age group largely because estimates for smaller strata lack precision. In previous pandemics, risk of death due to infl uenza has varied between countries, 9 possibly because of diff erences in the underlying chronic diseases and co-infections and access to antibiotics and intensive care. Therefore, to adjust sCFR estimates for diff erences in risk of death from respiratory disease in low-income versus high-income countries, we stratifi ed countries into three risk groups. We adjusted the estimated base mortality in each risk group using a riskgroup-specifi c respiratory mortality multiplier (RMM). The RMM was calculated by use of WHO's estimates of mortality rate for lower respiratory tract infection. 18 Thus, for each of the nine age-risk strata, we built a Monte Carlo probability model using SAS (version 9.2) with probability distributions defi ned according to the range of estimates of each parameter. We then estimated the number of respiratory deaths associated with 2009 pandemic infl uenza A H1N1 for each age and country-risk group by multiplying sAR, sCFR, RMM, and age group population.
Because pandemic H1N1 introduction was delayed in some countries by up to 8 months after the emergence of the virus in the Americas, 3 our approach implicitly estimates the mortality attributable to the pandemic virus during the fi rst 12 months of circulation with yearly cumulative attack rates in each country and not a contemporaneous complete calendar year.
Estimates of the cumulative sAR for the fi rst 12 months after virus introduction in each country were obtained from 17 sites in 13 countries-Bangladesh, Cambodia, Denmark, Germany, India, Kenya, the Netherlands, New Zealand, Nicaragua, Peru, the UK (England), the USA, and Vietnam. Data from the site in Cambodia were only gathered during 5 months and therefore were not included in the fi nal model. For most sites, sARs were calculated with raw data gathered with a standard template. Most sAR estimates were calculated from rates of outpatient visits for infl uenza-associated infl uenza-like illness divided by the proportion of individuals seeking medical care according to surveys of the use of healthcare patterns for respiratory illness during the pandemic; or from prospective, active community-based surveillance of respiratory illness with respiratory specimens that were obtained and tested for infl uenza viruses (detailed description of data sources and calculation methods is provided in appendix p 1). 14, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Estimates of the sARs were 4-33% for the paediatric age group, 0-22% for people aged 18-64 years, and 0-4% for those older than 64 years (table 1). We assumed that the true sAR of the 2009 pandemic infl uenza A H1N1 virus in all age groups was greater than zero; therefore, we set the lower bound of the sAR for people aged 18-64 years and older than 64 years as 1% in our model. Because of the huge variation in sARs within and between countries, we defi ned the probability of any particular sAR value in the model with a uniform distribution (ie, an equal probability of any sAR value in the range).
We obtained all available age-stratifi ed estimates of the 2009 pandemic infl uenza A H1N1 sCFR from six studies in Denmark, the Netherlands, New Zealand, the UK, and the USA (two estimates). 14, [23] [24] [25] [26] Sites in the UK, the USA, and Denmark were each adjusted for underreporting of deaths according to their own methods, whereas sites in the Netherlands and New Zealand estimated sCFR based on laboratory-confi rmed, reported deaths only. sCFR estimates were 0·002-0·013% for the paediatric age group, 0·018-0·159% for people aged 18-64 years, and 0·090-0·308% for those older than 64 years (table 1). Because the estimates of sCFR had wide and overlapping 95% CIs, we fi rst built a triangular distribu tion for each sCFR by setting the median of the triangular distribution as being equal to the point See Online for appendix estimate and the minimum and maximum values were set as the fi fth and 95th percentiles (tenth and 90th percentiles for US estimates), respectively. We then sampled each tri angular distribution an equal number of times to produce a sample of 10 000 points from which the fi nal model was sampled. As a sensitivity analysis, we re peated the same procedure using a uniform distribution for each sCFR estimate (results shown in appendix p 5).
RMM
To adjust for diff erences in risk of death from respiratory complications between countries, we developed an RMM for all age groups with WHO's 2008 country-specifi c estimated mortality rates for lower respiratory tract infection 18 and WHO's classifi cation of member states into fi ve mortality strata-very low child and adult mortality; low child and adult mortality; low child and high adult mortality; high child and adult mortality; and high child and very high adult mortality. 29 We defi ned the RMM for countries in the lowest WHO mortality stratum as equal to 1. We then calculated mortality rate ratios for all other countries as the mortality rate associated with lower respiratory tract infection in a given country divided by the median mortality associated with lower respiratory tract infection from the lowest WHO mortality stratum (24 per 100 000 individuals).
Mortality rate ratios are shown by country in appendix p 6. To minimise the eff ect of individual mortality rate ratios calculated with data of variable quality, we plotted the median mortality rate ratio for lower respiratory tract infection by WHO region and all-cause mortality stratum (appendix p 11). We then assigned countries to one of three risk groups on the basis of the resulting distribution and used the median mortality rate ratio from each group as the RMM for that group (with uncertainty defi ned by the IQR for the mortality rate ratios). These risk groups were all-African countries, non-African countries with high child and adult mortality, and all other countries (table 2) . Non-African countries with high child and adult mortality included Afghanistan, Bangladesh, Bhutan, Bolivia, Burma, Djibouti, Ecuador, Egypt, Guatemala, Haiti, India, Iraq, Maldives, Morocco, Nepal, Nicaragua, North Korea, Pakistan, Peru, Somalia, Sudan, Timor-Leste, and Yemen.
Population estimates
We used the UN's projected population estimates 30 for 2010 when available, and the US Census Bureau midyear population estimates 31 for 2010 for all remaining countries. Kosovo, Niue, and Vatican City were excluded from this analysis because no available age-stratifi ed population estimates were available.
Estimated respiratory mortality
We ran our Monte Carlo model 10 000 times to estimate mortality for each of the nine age-risk strata (a total of 90 000 iterations). We then applied each of the resulting 10 000 estimates for each age-risk stratum to population estimates for each country in the RMM stratum to calculate the number of deaths by age in each country. The distribution of mortality-rate estimates for each age-risk stratum was highly right skewed with the lower 75% of the estimates clustered within a narrow range of values and the upper 25% of estimates dispersed across a wide range of values (appendix p 12 shows an example of the distribution of estimates from one Monte Carlo simula tion). We summed the median and 25% and 75% estimates for each country and age group to calculate a global point estimate and range, respectively, by age group and WHO region.
Estimated cardiovascular mortality
Since infl uenza deaths can arise from respiratory or cardio vascular complications, we also estimated Countries with data inputs for symptomatic case fatality ratio ‡ ‡
USA (WI and NY) 24 § 0·013% (0·005-0·033) 0·159% (0·066-0·333) 0·090% (0·008-1·471)
References are for the general methods used for data gathering but might not include estimates for the period reported in this table. *Based on population-based surveillance or cohort study of respiratory illness with laboratory confi rmation of 2009 pandemic infl uenza A H1N1 virus infection. †Data from Kampong Cham were only gathered over 5 months; therefore, estimates of symptomatic attack rates from this site were not included in the fi nal model. ‡Based on statistical modelling by use of multiple data sources (see appendix p 1 for details). §Data were available for the following age groups: 0-14 years, 15-64 years, and greater than 64 years. ¶Derived from population-based surveillance for medically attended respiratory illness adjusted with the estimated proportion of people who sought care for respiratory illness. ||No available reference. **Outlier estimate excluded from the fi nal model. † †Based on estimate of seroprevalence of 2009 pandemic infl uenza A H1N1 virus infection adjusted with the estimated proportion of people who were seropositive and had symptoms of respiratory illness. ‡ ‡90% CI reported for USA and 95% CI for all other estimates. § §Only 95% CI used. . Second, we multiplied the median estimate of the ratio of cardio vascular to respiratory deaths for each age group by the base respiratory mortality rate in each country for people aged 18-64 years and older than 64 years to calculate the base cardiovascular mortality rate associated with 2009 pandemic infl uenza A H1N1 (unadjusted for diff erences between regions in risk of cardiovascular death). We then assessed diff erences in risk of death from cardiovascular disease between countries by calcu lating mortality rate ratios from WHO's 18 estimates of cardiovascular disease mortality rate based on the same method as for the RMM. Because the median mortality rate ratios for each regionmortality stratum were 1-2 (appendix p 13), we did not use a mortality multiplier for cardiovascular disease. Thus, for each age group in each country, we estimated the cardiovascular mortality rate associated with the 2009 pandemic infl uenza A H1N1 virus as the base respiratory mortality rate multiplied by the ratio of cardiovascular to respiratory deaths and population. All other countries, all ages 1 1 1 Uniform *Minimum and maximum values for each age group represent those of the sample of 10 000 points from which the fi nal model was sampled. †Refers to the representative sample built from an equal number of samples selected from each of the six sources for the estimates; fi rst, we built a triangular distribution setting the median of the triangular distribution as equal to the point estimate and the minimum and maximum set to the fi fth and 95th percentiles, respectively; and second, we sampled each triangular distribution an equal number of times to produce a sample of 10 000 points from which the fi nal model sampled. 32 To show the diff erences in the mortality burden for age groups between the 2009 H1N1 pandemic and seasonal infl uenza epidemics, we estimated YLL that would have been lost if the age distribution of people who died with 2009 pandemic infl uenza A H1N1 had been similar to the age distribution due to seasonal infl uenza. We assumed that during typical seasonal infl uenza epidemics, 1% of deaths occurred in people younger than 18 years, 9% in those aged 18-64 years, and 90% in people older than 64 years. 33, 34 We then redistributed our pandemic deaths according to this seasonal age distribution and estimated the YLL using the same equation as above.
Role of the funding source
We received no external funding for the analysis. The corresponding author had full access to all the data used in the analysis and had fi nal responsibility for the decision to submit for publication.
Results
The total of the median estimates of country-specifi c respiratory deaths associated with the 2009 pan demic infl uenza A H1N1 was 201 200 (range calculated by summing the 25th and 75th percentile estimates in each age group in each country), more than ten times the number of global deaths reported to WHO for the period April, 2009, to August, 2010 (table 3) . Summation of the fi fth and 95th percentile estimates in each age group and country would have resulted in an estimated range of 39 000-1 315 800 respiratory deaths associated with 2009 pandemic infl uenza A H1N1. Results from the sensitivity analysis in which a uniform distribution was used instead of a triangular distribution to sample from each sCFR range were broadly similar (appendix p 5). To demonstrate the eff ect of adjusting for diff erences in respiratory mortality, the calculation was repeated without the RMM, which resulted in an estimate of 112 900 respiratory deaths (range 61 500-218 200) associated with 2009 pandemic infl uenza A H1N1.
29% of the 201 200 estimated respiratory deaths associated with the 2009 pandemic infl uenza A H1N1 occurred in the African region (table 3) . The estimated mortality rate in the African region was about two to four times that in countries elsewhere (table 3) . The estimated range of respiratory deaths by country are shown in appendix p 15.
65% of 2009 pandemic infl uenza A H1N1 deaths worldwide were in individuals aged 18-64 years (60% of global population), although the age distribution varied by region. Overall, 13% of respiratory deaths associated with 2009 pandemic infl uenza A H1N1 were in people older than 64 years (8% of global population).
An additional 83 300 cardiovascular deaths (range 46 000-179 900) associated with the 2009 pandemic infl uenza A H1N1 were estimated to have occurred in people older than 17 years, resulting in a total of 284 400 respiratory and cardiovascular deaths (table 3) . 20% of these deaths occurred in people older than 64 years. With the inclusion of cardiovascular mortality, there was a reduction in the disparity in mortality associated with the pandemic by region, although the mortality rate in Africa remained about two to three times higher than elsewhere. Total numbers of respiratory and cardiovascular deaths by country are shown in appendix Estimated YLL were 9 707 000 during the fi rst 12 months of the pandemic (table 4). Southeast Asia was the region with the greatest YLL (table 4). Total YLL attributable to deaths associated with 2009 pandemic infl uenza A H1N1 was 3·4 times higher than if the age distribution of deaths had been similar to that during seasonal epidemics in developed countries where age-specifi c estimates of seasonal infl uenza mortality are available (table 4). The increase in YLL associated with 2009 pandemic infl uenza A H1N1 was due to the increased rate of death in people aged 64 years and younger.
Discussion
During the fi rst year of circulation of the 2009 pandemic infl uenza A H1N1 virus in each country, an estimated 105 700-395 600 people died of associated respiratory illness. Addition of cardiovascular deaths associated with 2009 pandemic infl uenza A H1N1 among people older than 17 years increased the mortality burden to 151 700-575 400 deaths (table 3) . Our global estimate was more than 15 times higher than the number of laboratoryconfi rmed deaths reported to WHO during the fi rst 16 months of the pandemic. A disproportionate number of total deaths from cardiovascular and respiratory diseases (51%) was estimated to have occurred in the African and southeast Asian regions where 38% of the world's population live and where data for infl uenza incidence are scarce. 35 Additionally, most deaths were reported in people aged 18-64 years, consistent with previous reports. 36 These fi ndings are in contrast to those for seasonal infl uenza deaths. Roughly 80-90% of these arise in people aged 65 years and older in Australia, Denmark, Singapore, and the USA, where age-stratifi ed estimates are available. 33, [37] [38] [39] However, the age distribution of seasonal infl uenza-associated deaths might diff er between settings because of diff erences in the prevalence of underlying illnesses (such as HIV/AIDS and tuberculosis) in younger adults in some low-income countries. The shift in the age distribution of deaths during the pandemic resulted in substantially more YLL than would have occurred if the age distribution of deaths had been similar to that of most seasonal infl uenza epidemics, consistent with obser vations from previous pandemics (panel).
Estimates from previous pandemics indicate that infl uenza mortality rates vary substantially between coun tries. 9, 47 Our accounting for diff erential risk of infl uenza-associated death between countries is supported by the fi ndings of Cohen and colleagues 6 that excess seasonal pneumonia and infl uenza mortality in people aged 65 years and older is at least three times higher in South Africa than in the USA. Further, data from the Americas and the western Pacifi c show that risk of death associated with the 2009 pandemic was up to six times higher in indigenous than in non-indigenous populations. 8 In both studies, 6,8 the prevalence of underlying disorders (including malnutrition in South Africa) and access to health care were postulated to contribute to the increased risk of infl uenza-associated death. Nair and colleagues 10 also estimated that mortality rates for infl uenza-associated acute lower respiratory tract infection in children younger than 5 years are three times higher in low-income countries than in highincome countries. WHO has estimated that an average of 0·004-0·008% per year of the world's population (250 000-500 000 people) die as a result of seasonal infl uenza. 48 Estimates of pandemic infl uenza mortality ranged from 0·03% of the world's population during the 1968 pandemic to 1-3% of the world's population during the 1918 pandemic. 7, 9, 47 We estimate that 0·001-0·007% of the world's population (n=6 891 433 594) died of respiratory complications associated with 2009 pandemic infl uenza A H1N1 during the fi rst year of virus circulation or 0·001-0·011% when cardiovascular deaths were included. However, our estimates are not directly comparable to those of mortality associated with seasonal and previous pandemic infl uenza for at least two reasons. First, the WHO estimate of global seasonal infl uenza mortality is an extrapolation of esti mates from high-income countries 48 without accounting for regional variation in risk of death from outcomes that might be associated with infl uenza, though details of the methods have not been provided. Second, reported estimates of global pandemic mortality include data from several years of pandemic virus circulation, whereas our estimate includes data for only the fi rst year of 2009 pandemic infl uenza A H1N1 virus circulation in each country.
We were unable to identify any factor or group of factors that allowed stratifi cation of countries into transmission risk groups, and therefore we assumed the same range of 2009 pandemic infl uenza A H1N1 sARs for all countries. This approach results in point estimates that underestimate or overestimate deaths in countries that had very high or very low transmission, respectively, but should produce ranges for most country-specifi c estimates that are likely to capture the true number of deaths in each country. For this reason, we present only ranges for our country-specifi c estimates. The assumption of a range of 2009 pandemic infl uenza A H1N1 sARs for all countries is less likely to bias our regional and global estimates.
Our model was limited by the scarcity of globally representative estimates of sAR and sCFR. We relied on only 16 direct estimates of 1 year sARs for 2009 infl uenza A H1N1 that varied greatly, and were likely to be aff ected by an unidentifi ed combination of factors such as diff erences in climate, population density, and population age structure. Data from serology studies of both symptomatic and asymptomatic infections support our fi ndings that the 2009 pandemic infl uenza A H1N1 attack rates varied substantially both within 4 and between countries. [49] [50] [51] [52] [53] [54] Second, we relied on only six estimates of sCFR from high-income countries because none were available from low-income or middle-income countries including China and India, which account for 37% of the world's population. Although the available estimates of sCFR were each calculated with diff erent methods for ascertaining the numerator (number of deaths associated with 2009 pandemic infl uenza A H1N1) and denominator (number of symptomatic 2009 pandemic infl uenza A H1N1 virus infections), most of these estimates were fairly similar. However, each sCFR estimate had a substantial amount of inherent uncertainty, particularly for the older than 64 years age group in which the denominator for the sCFR was lower than in other age groups. The uncertainty of the individual sCFR estimates widened the confi dence intervals of our fi nal estimates.
Panel: Research in context
Systematic review
We searched PubMed for reports of studies in any language from April, 2009, to March, 2012, with estimates of the number of deaths or mortality due to the 2009 pandemic infl uenza A H1N1. We identifi ed 12 studies from eight countries in Europe, the Americas, western Pacifi c, and Asia. 14, 17, 23, 25, [39] [40] [41] [42] [43] [44] [45] [46] In two studies from Australia (New South Wales) 42 and the UK, 41 no deaths were estimated based on the excess all-cause mortality during periods of infl uenza virus circulation. Two other UK studies were reported-in the England-only study, the estimated number of deaths was 390-490 25 and in the study of only England and Wales the estimate was 1556. 44 In one of the two studies from Mexico, the estimated mortality was 35 per 100 000 people in San Luis Potosi, 40 whereas in the other study the estimate was 6200 deaths for Mexico based on excess pneumonia and infl uenza mortality or 26 500 deaths based on excess all-cause mortality. 17 According to the estimates from two studies that included deaths in 2009 only, there were 6000 deaths in Bangladesh 45 and 0-256 deaths in Hong Kong, equal to an age-standardised mortality of 2·9-14·8 per 100 000 individuals. According to the estimates from the remaining studies, there were 8868-18 306 deaths in the USA, 14 121 or 151-473 in Denmark, 23, 39 and 266-958 in the Netherlands. 43
Interpretation
Our estimated ranges of deaths associated with 2009 pandemic infl uenza A H1N1 for each country overlap with reported estimates from Denmark (109-438 vs 151-473 or 121), the Netherlands (326-1289 vs 266-958), the USA (5834-22 697 vs 8868-18 306), China (Hong Kong only; 1·7-6·2 per 100 000 vs 2·9-14·8 per 100 000), and Bangladesh (3899-15 135 vs 6000). However, our estimated ranges are higher than most estimates from the UK (1237-4946 vs 0 for the UK or 390-490 for England or 1556 for England and Wales), and Australia (406-1589 vs mortality rate of 0 on the basis of excess all-cause deaths in the Hunter New England region) and lower than estimates from Mexico (1670-6105 vs 6200 excess pneumonia and infl uenza deaths or 26 000 excess all-cause deaths). Diff erences in study methods must be taken into account when estimates from these studies are compared. The results of our study add to the understanding of the global eff ect of the 2009 pandemic infl uenza A H1N1 because we have estimated the associated deaths in African and southeast Asian countries for which there is only one reported estimate from Bangladesh so far. We show that half of all global H1N1-associated respiratory and cardiovascular deaths could have occurred in Africa and southeast Asia and that mortality rates might have been two to three times higher in Africa than in other regions of the world.
The lack of infl uenza sCFR or mortality rate estimates for low-income and middle-income countries is an important knowledge gap in the understanding of the epidemiology of both seasonal and pandemic infl uenza. To overcome the lack of data to inform sCFR estimates for these settings, we developed an RMM from mortality rates for lower respiratory tract infection that are subject to several limitations. First, mortality rates consist of both disease incidence and case fatality rates. Thus, the RMM is aff ected by diff erences in the incidence of non-infl uenza respiratory infections, and the dearth of estimates of incidence of lower respiratory tract infection for most countries prevented us from adjusting for diff erences in incidence. Second, we used one RMM for all age groups because the age-stratifi ed rate ratios in the 0-17 year group were up to 58 times higher than the all-age ratios, probably due to a larger diff erence in incidence of non-infl uenza respiratory infections in this age group. By contrast, the all-age rate ratios were similar to ratios in the older age groups that had the most number of deaths associated with the 2009 pandemic infl uenza A H1N1. Because the relative risk of infl uenza-associated re spiratory death is likely to vary between age groups, use of one all-age RMM is likely to result in an underestimation of virus-associated mortality in children in low-income countries.
One additional potential methodological limitation of our analysis is that we summed the median and IQR estimates for each age group in each country to calculate a point estimate and range of the total number of deaths by country, region, and globally. The assumption with this approach is that symptomatic attack rates are positively correlated between age groups in each country (ie, it is unlikely for one age group to have an attack rate on the higher end of the global range of sARs and another age group to have an attack rate on the lower end of the global range). Had we summed the result of each Monte Carlo iteration for each age group in each country, then summed the results for each country, and taken the median and IQR of the distribution of the global estimates, our estimate would have been 25% higher. A fi nal potential limitation is that we assumed that the life expectancy of people who died with 2009 pandemic infl uenza A H1N1 was equal to that of people of the same age in the general population, although people who die from infl uenza might be more likely to have underlying disorders that are associated with a reduced life expectancy.
We estimated that 151 700-575 400 respiratory and cardiovascular deaths associated with 2009 pan demic infl uenza A H1N1 occurred during the fi rst year of virus circulation in every country in the world. Our fi ndings emphasise the need to improve the global response to future infl uenza pandemics and expand production and improve delivery of infl uenza vaccines to Africa and southeast Asia because these countries might have borne a disproportionate burden of pandemic mortality during the fi rst year of virus circulation. Additionally, continued eff orts to strengthen infl uenza surveillance worldwide, particularly for infl uenza-associated mortality, are needed both to guide seasonal infl uenza prevention strategies and to build infl uenza surveillance systems to provide better and more timely and globally representative data for infl uenza-associated mortality during future pandemics.
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